Back to Search
Start Over
Paliperidone palmitate versus oral antipsychotics in recently diagnosed schizophrenia.
- Source :
-
Schizophrenia Research . Dec2015, Vol. 169 Issue 1-3, p393-399. 7p. - Publication Year :
- 2015
-
Abstract
- <bold>Objective: </bold>Relapse and acute exacerbation are common in schizophrenia and may impact treatment response and outcome. Evidence is conflicting in respect to superiority of long-acting injectable antipsychotic therapies versus oral antipsychotics in relapse prevention. This randomized controlled study assessed the efficacy of paliperidone palmitate versus oral antipsychotics for relapse prevention.<bold>Method: </bold>Eligible patients with a recent diagnosis of schizophrenia (within 1-5 years) were randomized 1:1 to paliperidone palmitate (n=376) or oral antipsychotic monotherapy (n=388) and entered a 2-week initial acute oral treatment phase. Patients who met predefined response criteria were eligible to enter the 24-month rater-blinded core treatment phase. Patients were evaluated for relapse, symptoms, functioning, quality of life, treatment satisfaction, and tolerability.<bold>Results: </bold>In the core treatment phase, time to relapse was significantly longer in the paliperidone palmitate (n=352) compared with the oral antipsychotics arm (n=363): 85% of patients were relapse-free at 469 versus 249 days (P=0.019). Significantly fewer patients receiving paliperidone palmitate met the relapse criteria (52 [14.8%] versus 76 [20.9%, oral antipsychotics]; P=0.032), representing a 29.4% relative risk reduction. For paliperidone palmitate, a significantly greater improvement in Positive and Negative Syndrome Scale total score on Day 8 (P=0.021) and a trend at endpoint (P=0.075) were observed. Functioning improvements were comparable between treatment arms. No new safety signals were identified.<bold>Conclusion: </bold>The observed time to relapse superiority of paliperidone palmitate over oral antipsychotics provides further evidence for the value of long-acting injectable antipsychotic therapies in the treatment of schizophrenia, including during the early stages of illness. [ABSTRACT FROM AUTHOR]
- Subjects :
- *DOPAMINE antagonists
*ANTIPSYCHOTIC agents
*SCHIZOPHRENIA treatment
*DISEASE exacerbation
*DISEASE relapse
*HEALTH outcome assessment
*COMPARATIVE studies
*RESEARCH methodology
*MEDICAL cooperation
*ORAL drug administration
*PSYCHOLOGICAL tests
*RESEARCH
*TIME
*EVALUATION research
*RANDOMIZED controlled trials
*TREATMENT effectiveness
*KAPLAN-Meier estimator
DRUG therapy for schizophrenia
Subjects
Details
- Language :
- English
- ISSN :
- 09209964
- Volume :
- 169
- Issue :
- 1-3
- Database :
- Academic Search Index
- Journal :
- Schizophrenia Research
- Publication Type :
- Academic Journal
- Accession number :
- 111419305
- Full Text :
- https://doi.org/10.1016/j.schres.2015.08.015